Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Lymphoid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Biphenotypic, Acute 1 Hodgkin Disease 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 47 Cisplatin 32 pembrolizumab 28 Paclitaxel 13 Docetaxel 13 avelumab 12 Mitomycin 12 atezolizumab 11 Nivolumab 11 Cystectomy 10 Carboplatin 9 durvalumab 7 Sunitinib 7 apaziquone 6 Doxorubicin 6 BCG Vaccine 6 5-aminolevulinic acid hexyl ester 6 Vinblastine 5 Radiation 5 Platinum 5 Methotrexate 5 Magnetic Resonance Spectroscopy 5 Albumin-Bound Paclitaxel 5 Taxes 4 Standard of Care 4 Sorafenib 4 Radiotherapy 4 Fluorouracil 4 Erlotinib Hydrochloride 4 1,2-diaminocyclohexaneplatinum II citrate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Urinary Bladder Neoplasms × lirilumab × Clear all

NCT03532451 2024-09-19

PrE0807

PrECOG, LLC.

Phase 1 Completed

43 enrolled 15 charts

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡